2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Indoleamine 2,3-Dioxygenase (IDO)

Indoleamine 2,3-Dioxygenase (IDO)

Indoleamine 2,3-Dioxygenase (IDO)

Related Products

PDF 0.8 MB

Indoleamine 2, 3-dioxygenase (IDO) is an inflammatory cytokine-inducible rate-limiting enzyme of the tryptophan (Trp) catabolism, which is involved in the inhibition of intracellular pathogen replication as well as in immunomodulation. To date, three types of tryptophan-metabolizing enzymes have been identified: IDO1, IDO2 and tryptophan 2,3-dioxygenase 2.

IDO is an intracellular enzyme that is constitutively expressed in several human and mouse cells. Being present in innate immune cells, such as Mos and dendritic cells (DCs), IDO catalyzes the initial rate-limiting step of tryptophan (Trp) catabolism, thus leading to the production of immunoregulatory catabolites (collectively known as kynurenines).

The IDO gene promoter contains multiple sequence elements that confer responsiveness to proinflammatory mediators, thereby demonstrating the strong correlation between inflammation and induced IDO expression.

Indoleamine 2,3-Dioxygenase (IDO) Isoform Specific Products:

Indoleamine 2,3-Dioxygenase (IDO) Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-147772
    ZC0101
    		Inhibitor
    ZC0101 is a potent, orally active IDO1 and TrxR dual inhibitor with IC50 values of 0.084 μM and 7.98 μM, respectively. ZC0101 effectively induces apoptosis and ROS accumulation in cancer cells.
    ZC0101
  • HY-120742
    MMG-0358
    		Inhibitor
    MMG-0358 is a potent IDO1 inhibitor. MMG-0358 shows IC50 values of 2 nM in a cellular assay on mIDO1, 80 nM in a cellular assay on hIDO1, 330 nM in an enzymatic assay on hIDO1 at pH 6.5, and 71 nM in an enzymatic assay on hIDO1 at pH 7.4.
    MMG-0358
  • HY-173513
    IDO1/TDO-IN-8
    		Inhibitor
    IDO1/TDO-IN-8 (Compound CZ-17) is a dual IDO1 and TDO inhibitor that can penetrate the blood-brain barrier, with EC50 values of 0.33 μM and 1.78 μM, respectively. IDO1/TDO-IN-8 reduces the kynurenine/tryptophan ratio by regulating the kynurenine pathway of tryptophan metabolism. IDO1/TDO-IN-8 has a neuroprotective effect and can alleviate motor dysfunction and improve depressive behavior. IDO1/TDO-IN-8 can be used in the study of Parkinson's disease combined with depression.
    IDO1/TDO-IN-8
  • HY-112164A
    IACS-8968 R-enantiomer
    		Inhibitor 98.48%
    IACS-8968 (R-enantiomer) is the R-enantiomer of IACS-8968. IACS-8968 is a dual IDO and TDO inhibitor, with pIC50s of 6.43 for IDO and <5 for TDO, respectively.
    IACS-8968 R-enantiomer
  • HY-N16372
    Pronqodine A
    		Inhibitor
    Pronqodine A is an Indoleamine 2,3-Dioxygenase (IDO) inhibitor, with an IC50 of 131.5 nM. Pronqodine A inhibits bradykinin-induced release of PGE2, 6-keto-prostaglandin F1α, PGD2 and induces the production of reactive oxygen species (ROS) in human synovial sarcoma SW982 cells. Pronqodine A is a good substrate for human quinone reductase NQO1. Pronqodine A can be used for the study of inflammation.
    Pronqodine A
  • HY-113568
    CAY10581
    		Inhibitor
    CAY10581, a pyranonaphthoquinone derivative, is a highly specific and reversible uncompetitive IDO Inhibitor with an IC50 of 55 nM.
    CAY10581
  • HY-184027
    IDO1/TDO-IN-12
    		Inhibitor
    IDO1/TDO-IN-12 is an IDO1/TDO2 inhibitor with IC50 values of 0.825 and 4.04 μM, respectively. IDO1/TDO-IN-12 interacts with the ferrous heme cofactor in IDO1 as a non-competitive tryptophan inhibitor. IDO1/TDO-IN-12 inhibits nitric oxide production in LPS (HY-D1056)-stimulated immune cells. IDO1/TDO-IN-12 relieves pulmonary edema and lung injury in LPS-induced mouse models. IDO1/TDO-IN-12 can be used for the research of acute lung injury (ALI).
    IDO1/TDO-IN-12
  • HY-184134
    IDO1/TDO-IN-16
    		Inhibitor
    IDO1/TDO-IN-16 (Fig.1 Compound 4) is a dual inhibitor of IDO1 and TDO. IDO1/TDO-IN-16 is applicable for cancer research.
    IDO1/TDO-IN-16
  • HY-184135
    IDO/TDO-IN-2
    		Inhibitor
    IDO1/TDO-IN-2 is an IDO1/TDO inhibitor with both human IDO1 and human TDO pIC50 ≥5.50. IDO1/TDO-IN-2 can be used for the research of cancer.
    IDO/TDO-IN-2
  • HY-161996
    IDO1-IN-25
    		Inhibitor
    IDO1-IN-25 is a dual inhibitor of IDO1/TDO2, with IC50 values of 0.17 μM and 3.2 μM, respectively. IDO1-IN-25 can effectively inhibit the production of NO in RAW264.7 cells stimulated by lipopolysaccharide (LPS). IDO1-IN-25 can exert anti-inflammatory effects in a mouse ear edema acute inflammation model induced by croton oil.
    IDO1-IN-25
  • HY-184028
    IDO1-IN-37
    		Inhibitor
    IDO1/TDO-IN-13 (Compound 40) is a selective, non-competitive IDO1 inhibitor with an IC50 of 0.106 μM against IDO1. IDO1/TDO-IN-13 is applicable to the research of inflammatory diseases.
    IDO1-IN-37
  • HY-177784
    iDeg-3
    		Degrader
    iDeg-3 is a selective molecular glue degrader that targets IDO1. iDeg-3 can competitively bind to the heme binding site of apo-IDO1, preventing heme binding and inhibiting the enzymatic reaction that converts tryptophan into kynurenine by IDO1 (IC50 = 46 nM). iDeg-3 can be used for the researches of cancer, infection and neurological disease, such as melanoma.
    iDeg-3
  • HY-183317
    IDO1-IN-34
    		Inhibitor
    IDO1-IN-34 is a selective IDO1 inhibitor with an IC50 of 0.093 μM. IDO1-IN-34 exhibits cytotoxicity against various cancer cell lines. IDO1-IN-34 inhibits the kynurenine (kynurenine) pathway and activates IL-2. IDO1-IN-34 induces cell apoptosis via the endogenous mitochondrial pathway, while increasing the levels of cytochrome c, caspase-3, caspase-9 and PARP-1. IDO1-IN-34 can be used for research on liver cancer, lung cancer, breast cancer, prostate cancer, colon cancer and leukemia.
    IDO1-IN-34
  • HY-178024
    IDO1-IN-29
    		Inhibitor
    IDO1-IN-29 (Compound MQ-1n) is a Apo-IDO1 inhibitor with an IC50 of 0.29  μM. IDO1-IN-29 selectively targets apo-IDO1 and disrupts heme binding. IDO1-IN-29 can be used for cancers research.
    IDO1-IN-29
  • HY-160025
    IDO antagonist-1
    		Antagonist
    IDO antagonist-1 (compound 163) is an antagonist of IDO . IDO antagonist-1 inhibits pancreatic adenocarcinoma cells growth in C57BL/6 mice.
    IDO antagonist-1
  • HY-156400
    IDO1-IN-23
    		Inhibitor
    IDO1-IN-23 (compound 41) is a potent human IDO1 inhibitor with an IC50 value of 13 μM.
    IDO1-IN-23
  • HY-D0033
    Roxyl-9
    		Inhibitor 99.22%
    Roxyl-9 is a IDO1 (Indoleamine 2,3-dioxygenase 1) inhibitor.
    Roxyl-9
  • HY-184104
    IDO1/TDO-IN-17
    		Inhibitor
    IDO1/TDO-IN-17 is an IDO1/TDO inhibitor with human IDO1 IC50 ~280 μmol/L and human TDO IC50 204 μmol/L. IDO1/TDO-IN-17 binds to the heme-iron of IDO1. IDO1/TDO-IN-17 can be used for the research of cancer.
    IDO1/TDO-IN-17
  • HY-129749
    IDO-IN-13
    		Inhibitor
    IDO-IN-13 is a potent indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor with an EC50 of 17 nM, extracted from patent WO2019040102A1, example 43.
    IDO-IN-13
  • HY-184129A
    (E)-IDO1/TDO-IN-15
    		Inhibitor
    (E)-IDO1/TDO-IN-15 is an isomer of IDO1/TDO-IN-15 (HY-184129). IDO1/TDO-IN-15 is a dual IDO1/TDO inhibitor with an IDO1 IC50 of 0.19 μM and a TDO IC50 of 0.37 μM. (E)-IDO1/TDO-IN-15 is applicable to the research of cancer and Alzheimer's disease.
    (E)-IDO1/TDO-IN-15
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity
Indoleamine 2,3-Dioxygenase (IDO) Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.